Mer­ck’s Keytru­da nears $21B in sales, dou­bles down on com­bo tri­als

Mer­ck’s can­cer im­munother­a­py Keytru­da notched sales of $20.9 bil­lion in 2022, ce­ment­ing its sta­tus as one of the world’s top-sell­ing drugs. How­ev­er, it’s far from rest­ing on that ac­com­plish­ment.

Mer­ck ex­ec­u­tives tout­ed nine on­go­ing tri­als in its an­nu­al earn­ings call on Thurs­day, in­clud­ing five stud­ies in Phase III, for Keytru­da (pem­brolizum­ab) in com­bi­na­tion with oth­er im­muno-on­col­o­gy drugs. The tri­als in­clude com­bi­na­tions with Mer­ck’s own de­vel­op­ments as well as oth­er phar­ma com­pa­nies’ can­di­dates, in­clud­ing its melanoma col­lab­o­ra­tion with Mod­er­na and its mR­NA tech­nol­o­gy plus Keytru­da, aimed at cre­at­ing a per­son­al­ized vac­cine treat­ment to re­duce the risk of can­cer re­cur­rence or death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER